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Abstract
Background: Stereotactic radiosurgery (SRS) is an alternative to post-operative whole brain radiation therapy
(WBRT) following resection of brain metastases. At our institution, CyberKnife (CK) is considered for local treatment
of large cavities ≥2 cm. In this study, we aimed to evaluate patterns of failure and characterize patients best suited
to treatment with this approach.
Methods: We retrospectively reviewed 30 patients treated with CK to 33 resection cavities ≥2 cm between 2011
and 2014. Patterns of intracranial failure were analyzed in 26 patients with post-treatment imaging. Survival was
estimated by the Kaplan-Meier method and prognostic factors examined with log-rank test and Cox proportional
hazards model.
Results: The most frequent histologies were lung (43 %) and breast (20 %). Median treatment volume was 25.1 cm3
(range 4.7–90.9 cm3) and median maximal postoperative cavity diameter was 3.8 cm (range 2.8–6.7). The most
common treatment was 30 Gy in 5 fractions prescribed to the 75 % isodose line. Median follow up for the entire
cohort was 9.5 months (range 1.0–34.3). Local failure developed in 7 treated cavities (24 %). Neither cavity volume
nor CK treatment volume was associated with local failure. Distant brain failure occurred in 20 cases (62 %) at a
median of 4.2 months. There were increased rates of distant failure in patients who initially presented with
synchronous metastases (p = 0.02). Leptomeningeal carcinomatosis (LMC) developed in 9 cases, (34 %). Salvage
WBRT was performed in 5 cases (17 %) at a median of 5.2 months from CK. Median overall survival was
10.1 months from treatment.
Conclusions: This study suggests that adjuvant CK is a reasonable strategy to achieve local control in large
resection cavities. Patients with synchronous metastases at the time of CK may be at higher risk for distant brain
failure. The majority of cases were spared or delayed WBRT with the use of local CK therapy.
Keywords: Brain metastases, Radiosurgery, CyberKnife
Background
Approximately 20–40 % of patients with cancer will
develop intracranial metastases [1]. Treatment options
for these patients include surgery, whole brain radiation
therapy (WBRT) and stereotactic radiosurgery (SRS).
For patients with large intracranial metastases, local
control with single modality treatment is poor. Studies
have shown <10 % complete response rate with WBRT
for tumors approximately 2 cm in diameter [2]. Local
control is maintained in less than 50 % of tumors larger
than 2 cm after radiosurgery alone [3]. Randomized
studies have demonstrated that WBRT following surgical
resection of a solitary metastasis decreases the rate of
local recurrence within the surgical bed as well as dis-
tant recurrence within the brain [4]. However, WBRT is
associated with decreased cognitive function and quality
of life without a proven overall survival benefit [5, 6].
SRS to the surgical bed is an emerging alternative
that may allow WBRT to be deferred for a select
group of patients.
* Correspondence: Michelle.Alonso-Basanta@uphs.upenn.edu
1Department of Radiation Oncology, University of Pennsylvania, TRC-2 West,
3400 Civic Center Boulevard, Philadelphia, PA 19104, USA
Full list of author information is available at the end of the article
© 2015 Vogel et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Vogel et al. Radiation Oncology  (2015) 10:221 
DOI 10.1186/s13014-015-0523-4
Large resection cavities are less amenable to single
fraction SRS given the high risk of radiation damage
with increasing cavity size [7]. Fractionated SRS follow-
ing surgical resection has been shown to be feasible and
safe utilizing linear accelerator-based and CyberKnife
(CK) technologies for cavities greater than 3 cm [8–10].
However, there is limited information on optimal patient
selection for this treatment approach. In particular,
questions remain regarding risk of local and distant fail-
ure, especially leptomeningeal carcinomatosis (LMC). In
this study, we report outcomes following single or multi-
fraction SRS for large brain metastases after surgical
resection. We quantify local control and assess patient




Patients were considered for SRS following surgical
resection. Patients recommended for SRS had low intra-
cranial metastatic burden (1–4 metastases) and good
overall prognosis as judged by performance status, status
of extracranial disease, age, and histology [11]. CK was
considered for lesions ≥ 2 cm, lesions with gross residual
or recurrent disease, and lesions near critical structures.
SRS was ideally performed after full post-operative
wound healing 4–6 weeks from the time of resection.
With the approval of the institutional review board, we
retrospectively analyzed medical records of all patients
treated with single or multiple fraction CyberKnife (CK)
SRS to surgical beds of intracranial metastases ≥2 cm at
the time of radiosurgery. Cases were performed between
2011 and 2014 at the Pennsylvania Hospital (University of
Pennsylvania Health System). Patients with a history of
WBRT prior to CK or with a plan for CK followed by
WBRT were excluded from this study. Patients with syn-
chronous unresected lesions treated with SRS alone were
included in this study.
Data collection
All clinical data was obtained from electronic medical
records and Social Security Death Index. The status of
extracranial disease was defined as none, stable, or
progressive based on systemic imaging prior to CK.
Those who were diagnosed at the time of intracranial
disease or who had no treatment to their primary site
were characterized as newly diagnosed. Post-operative
MRI was obtained 24–48 h after resection in each
case. Gross total resection (GTR) was defined as
no residual enhancing tumor after surgery on MRI.
Graded prognostic assessment (GPA) class was assigned
to each patient according to methods described by
Sperduto et al. [11].
Radiosurgical technique and follow up
The CyberKnife (Accuray, Sunnyvale, CA) was used
to deliver all radiosurgical treatments. Brain MRI was
obtained at 1-mm slices with gadolinium contrast. The
MRI scan was fused to the computed tomography scan
(CT) for target delineation. The gross tumor volume
(GTV) was contoured as the edge of the resection cavity
including contrast enhancement. The clinical tumor vol-
ume (CTV) was an expansion of 2–3 mm margin added
to the GTV. Planning target volume (PTV) was the
same as the CTV.
Table 1 Patient characteristics
Characteristic Value
Sexa
Male (%) 15 (50)
Female (%) 15 (50)
Age in years at CK
Median (range) 58 (28–97)
Primary tumora
NSCLC (%) 12 (40)
SCLC (%) 1 (3)
Breast (%) 6 (20)
Melanoma (%) 4 (13)
Other (%) 7 (23)
Extracranial diseasea
Newly diagnosed/ progressing (%) 15 (50)







Postoperative diameter in cm
Median (range) 3.8 (2.8–6.7)
Surgery extentb
GTR (%) 19 (58)
STR (%) 14 (42)
Synchronous intact metsa
Yes (%) 10 (33)
No (%) 20 (67)
Weeks from resection to CK
Median (range) 7 (4–19)
Preop preoperative, CK Cyberknife, GTR gross total resection, STR subtotal
resection, mets metastases, NSCLC non-small cell lung cancer, SCLC small cell
lung cancer, GI gastrointestinal
aN = 30 patients
bN = 33 cases
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Dose was based on the size of the PTV and preference
of the treating physician. Larger cavities were typically
treated to 30 Gy in five fractions and smaller cavities to
24 Gy in three fractions as has been previously described
[12]. With a plan maximal dose of 100 %, doses were
prescribed to the 55–90 % isodose lines. The PTV was
covered by at least 95 % of the dose in all cases. Con-
formality index was typically between 1.1 and 1.2, and
smaller than 1.3. The number of beams was between
100 and 200 and treatment times were kept under 1 h.
After CK, follow-up included clinical visits at 1 month
and then 3-month intervals. Surveillance MRI was ob-
tained 2–3 months following CK and subsequently every
3 months. Local failure was defined as new and progres-
sive nodular enhancement in the resection bed over a
minimum follow-up of 4 months, or two consecutive
MRI scans. Radionecrosis was evaluated using dynamic
contrast-enhanced perfusion imaging (DCE-MRI) and
magnetic resonance spectroscopy (MRS). Radionecrosis
rather than local progression was suggested by 1) low
cerebral blood volume 2) increased lactate/creatine ratio
and decreased choline/creatine ratio and 3) regression or
stability over a minimum follow-up of 4 months without
additional treatment [13, 14]. Clinical decisions regarding
local progression versus radionecrosis were made in a
multidisciplinary setting including input from a diagnostic
radiologist. Distant failure was defined as new brain me-
tastases away from the surgical cavity or development of
LMC, diagnosed based on MRI, clinical symptoms, and/
or cerebrospinal fluid analysis.
Statistical analysis
Statistical tests were performed using Stata 13.1 (Stata-
Corp). Overall survival was estimated using the Kaplan-
Meier method with all cases included in the analysis.
Living patients or those lost to follow-up were censored
at the date of last clinical encounter. Local and distant
failure was examined by the Kaplan-Meier method in
cases where post-CK imaging was available. Patients
who received salvage WBRT were censored at last MRI
prior to WBRT for the failure analysis. Univariable
analyses were computed using log-rank test and a p
value ≤ 0.1 was considered statistically significant.
Multivariable analysis was performed via the Cox
proportional hazards ratio and p ≤ 0.05 was considered
statistically significant. For this exploratory, hypothesis-
generating study we made no adjustment for multiple
comparisons.
Table 2 Fractionation schemes
No. of fractions N Median dose (Gy) Median dose per fraction (Gy) Median diameter (cm) Median isodose line (%)
1 2 18.5 (16–21) 18.5 (16–21) 2.8 (2.8–2.9) 61 (55–66)
3 5 24 (24) 8 (8) 3.6 (3.1–4.5) 76 (71–79)
5 26 30 (25–35) 6 (5–7) 4.2 (3.2–6.7) 76 (64–88)
No. number, PTV planning treatment volume
Fig. 1 Freedom from local intracranial progression after CK
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Results and discussion
A total of 30 patients were treated with CK to 33 resec-
tion cavities. Fifteen patients (50 %) were male and 15
(50 %) were female. The most frequent histologies were
lung (43 %) and breast (20 %). Median GPA was 2.5
(range 1–4). Gross total resection (GTR) was achieved
in 19 (58 %) cases. A median of one synchronous metas-
tasis was observed in 10 patients (range 1–3) [Table 1].
SRS was performed a median of 7 weeks from resection
(range 4–19 weeks). Causes of delay included wound
infection (n = 1), pulmonary embolism (n = 1), treat-
ment of primary site (n = 1), systemic staging (n = 2),
insurance referral delay (n = 2), and intracranial re-
staging (n = 7). At the time of treatment planning,
interval growth was observed in 13 cavities.
The median SRS dose to the resection cavity was
30 Gy (range 16–35) delivered in 1 to 5 fractions (me-
dian, 5 fractions). Median cavity volume was 17.5 cm3
(range 2.4–69.8 cm3) and median treatment volume was
25.1 cm3 (range 4.7–90.9 cm3). Median maximal postop-
erative cavity diameter was 3.8 cm (range 2.8–6.7)
[Table 2].
The median clinical follow up for the entire cohort of
30 cases was 9.5 months (range 1.0–34.3), and for the 13
Fig. 2 Freedom from distant intracranial progression after CK
Fig. 3 Survival after CK
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living patients was 16.9 months (range 4.4–35.2). Twenty-
six patients with 29 treated cavities were followed with
serial imaging.
Local failure occurred in 7 cavities, for a crude rate of
24 %. Median time to local failure was 3.4 months in the
cases that failed. Six-month and one-year actuarial local
control were 82.3 and 68.5 % [Fig. 1]. Six of the 7 cases
with local failure had images available for evaluation.
Failure occurred within the GTV in 5 instances and
3 mm from the GTV in 1 case. Evaluation of preopera-
tive tumor diameter, postoperative tumor diameter,
GTV, and PTV at a variety of cut-off points showed no
association with local failure (p > 0.2).
Of the 26 patients with available follow-up imaging,
distant brain failure occurred in 16 (62 %) at a median
of 4.2 months from CK. Actuarial 6-month and 1-year
distant brain failure were 55.3 and 73.9 % [Fig. 2]. On
univariable analysis, presence of synchronous metasta-
ses at the time of diagnosis (p = 0.04), dose per frac-
tion <6 Gy (p = 0.07), and total dose <30 Gy (p = 0.1)
were associated with distant failure. On multivariable
analysis, synchronous metastases at diagnosis was
significantly associated with distant failure (p = 0.02,
95 % CI 1.33–14.5).
Among the 26 cases with follow-up imaging, 9 devel-
oped leptominengeal disease, for a crude rate of 34 %.
On univariable analysis, simultaneous resection of
multiple metastases (p = 0.01) and >50 days delay to
CK (p = 0.03) were associated with LMC. There was
no association with tumor histology, cavity diameter,
cavity volume, or cavity location (p > 0.3). On multi-
variable analysis, no variable was significantly associ-
ated with LMC.
By Kaplan-Meier analysis, the median overall survival
was 10.1 months from CK [Fig. 3]. On univariable ana-
lysis, male gender (p = 0.01), the presence of synchronous
metastases (p = 0.07), GPA ≤ 3 (p = 0.04) and age >60 years
(p = 0.1) were statistically significantly associated with
overall survival. On multivariable analysis, male gender
remained statistically significant (p = 0.01).
Two patients underwent upfront resection of two sim-
ultaneous lesions. Eight were treated with concurrent
SRS for synchronous, unresected metastases found at
the time of CK. Seven patients underwent additional
Fig. 4 Outcomes after Initial SRS
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SRS [Fig. 4]. Five of 30 total patients (17 %) were treated
with salvage WBRT at a median of 5.2 months from CK.
Patients with leptomeningeal disease were significantly
more likely to receive salvage WBRT (p = 0.001).
Three patients developed clinically significant radione-
crosis requiring treatment with steroids (10 %). None
had neurosurgical resection. Two patients had new onset
seizures within 3 months of CK.
Discussion
For patients treated with surgical resection of intra-
cranial metastases, whole brain radiation therapy has
been shown to improve intracranial control without
an overall survival benefit [5, 7]. Neurocognitive de-
cline and decreased quality of life have been associ-
ated with whole brain radiation and led to increasing
use of local therapies to delay or defer WBRT after
resection [6].
Numerous studies have reported outcomes of single
fraction stereotactic radiosurgery to small resection cav-
ities in patients without prior WBRT [Table 3]. One year
actuarial local control rates range from 78 to 100 % and
distant failures occur in 33–66 % of patients [15, 16, 17,
18]. Whole brain radiation is reported as salvage therapy
in approximately one third of patients.
Large lesions are less amenable to single fraction treat-
ment given increasing dose to surrounding normal tissue
and risk of radiation necrosis, especially for lesions >3 cm
[5]. Previous studies have established safety and efficacy of
fractionated SRS in treatment of large brain metastases,
with rates of radionecrosis from 2 to 6 % [8–10]. However,
there are few reports describing outcomes for patients
with large resection cavities treated with fractionated SRS
without WBRT [Table 4]. Reported cases are characterized
by cavity volumes ranging from 8.7 to 29.5 cm3 and low
rates of radionecrosis, from 3 to 9 % [19–23]. Series of pa-
tients treated with predominantly fractionated regimens
report 71–91 % local control, comparable to single frac-
tion series. Similarly, approximately one third of patients
are salvaged with whole brain radiation.
In some series, increased risk of local failure is seen
with increasing preoperative diameter or cavity size
[Table 5]. Brennan et al. report 39.1 % local failure in pa-
tients with tumors ≥3 cm as compared to 7.5 % with
maximal diameter <3 cm [24]. Prabhu et al. report a
hazard ratio of 1.04 for local recurrence with increasing
PTV volume [25]. In these series, patients were predom-
inantly treated with single fraction SRS. Our series con-
sisted of patients with large lesions treated most often
with fractionated SRS. Increased risk of local failure was
Table 3 Literature of single fraction SRS to the resection cavity
Authors & year No. cavities Treatment modality Median dose (Gy) Crude LF (%) DF (%) Salvage WBRT (%) LMC (%) MS (mos)
Iwai et al., 2008 [19] 21 GK 17 24 48 NR 24 20
Do et al., 2009 [26] 33 LINAC 15 12 63 47 NR 12
Jagannathan et al., 2009 [27] 47 GK 19 7 87 28 NR 11
Karlovits et al., 2009 [28] 52 LINAC 15 8 55 31 NR 15
Limbrick et al., 2009 [29] 16 GK 20 27 60 40 NR 20
Hwang et al., 2010 [30] 25 GK 15–20a 0 33 NR NR 15
Kalani et al., 2010 [31] 68 GK 15 21 NR NR NR 13.2
Jensen et al., 2011 [15] 112 GK 17 13 54 37 7.5 10.9
Rwigema et al., 2011 [20] 77 CK 18 26 47 26 NR 14.5
Kelly et al., 2012 [32] 18 LINAC 18 11 35 24 NR N/A
Ogiwara et al., 2012 [33] 56 GK 16 9 38 14 NR 21
Prabhu et al., 2012 [22]b 64 LINAC 18 17 NR NR NR 13
Robbins et al., 2012 [16] 85 LINAC 16 19 55 35 8.2 12
Broemme et al., 2013 [23]b 44 LINAC 17c, 24d 9 66 36 NR 15.9
Hartford et al., 2013 [35] 49 LINAC 10 16 63 45 NR NR
Luther et al., 2013 [17] 120 GK 16 14 40 NR NR NR
Brennan et al., 2014 [34] 40 LINAC 18 30 47 NR NR 14.7
Ojerholm et al., 2014 [18] 96 GK 16 18 54 33 14 22.3
No. number, GK Gamma Knife, LINAC linear accelerator, CK Cyberknife, LF local failure, DF distant failure, MS median survival, LMC leptomeningeal carcinomatosis,
mos months, NR not reported, N/A not applicable
aReported range
bMajority single fraction SRS
cMedian single fraction dose
dMedian multi fraction dose
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not seen in association with increasing tumor diameter,
increasing cavity size, or larger treatment volumes.
Distant failures in reported series of fractionated
stereotactic radiosurgery range from 53 to 64 % [26, 27,
28]. In our series, distant failure occurred in 62 % of
treated patients. Our study did not show any correlation
between cavity size and increased distant failure, al-
though we did observe increased rates of distant failure
with synchronous metastases at the time of resection.
Other studies have shown a similar trend towards in-
creased distant failure when multiple metastases are
present at the time of initial SRS [29, 30]. As in other
series, the majority of patients were salvaged with add-
itional SRS and spared WBRT.
Rates of distant failure from leptomeningeal carcin-
omatosis have been less frequently reported. Given the
lack of data for this entity, our study adds to the litera-
ture in regards to rates after local therapy. For patients
treated with single fractions, rates range from 4.5 to
24 % [31, 32, 33, 34]. A single report of patients treated
predominantly with multi-fraction SRS demonstrated a
rate of 6 % [35]. Our rate of 34 % is higher than that re-
ported for surgical cavities treated with CK and GK. This
risk has been associated previously with breast histology
and infratentorial location [18, 19]. In this cohort, hist-
ology, location, and cavity size had no association with
risk of LMC. Clinical factors associated with LMC re-
main to be characterized.
Table 5 Significantly associated clinical characteristics
Authors LF DF LMC OS
Iwai et al. [19] Dose < 18Gy N/A Infratentorial location N/A
Jagannathan et al. [27] Greater treated volume N/A N/A Systemic progression
Karlovits et al. [31] N/A N/A N/A >1 intracranial metastasis
Extracranial disease
Jensen et al. [15] Preop diameter > 3 cm Dose <35Gy N/A N/A
Rwigema et al. [20] Greater PTV N/A N/A Age
RPA score
Choi et al. [21] N/A Melanoma histology N/A KPSPreop diameter
Ogiwara et al. [33] N/A N/A N/A Extracranial metastases
Prabhu et al. [22] Larger PTV volume N/A N/A N/A
Marginal dose <18 Gy
Brennan et al. [34] NSCLC histology Infratentorial location N/A N/A
Preop diameter > 3 cm
Dural/ pial involvement
Hartford et al. [35] Preop diameter≥ 2 cm Preop diameter≥ 2 cm N/A GPA ≤1
Ojerholm et al. [18] Preop diameter≥ 3 cm N/A Breast histology New diagnosis or untreated primary
Infratentorial location
Ling et al. [25] N/A Uncontrolled systemic disease N/A Increasing no. metastases
Melanoma histology Uncontrolled systemic disease
Increasing no. brain metastases
Present study N/A Synchronous metastases N/A Male gender
LF local failure, N/A not applicable, PTV planning treatment volume, Preop preoperative, LMC leptomeningeal carcinomatosis, CK Cyberknife, OS overall survival,
RPA recursive partitioning analysis, KPS Karnofsky performance status, GPA graded prognostic assessment, no. number
Table 4 Literature of single or multiple fraction SRS to resection cavity
Authors & year No. cavities Treatment modality Median dose (Gy) Crude LF (%) DF (%) Salvage WBRT (%) LMC (%) MS (mo)
Choi et al., 2012 [21]a 102 CK 16b 11 53 28 NR 15.6
Minniti et al., 2013 [24] 101 LINAC 27 8 53 27 NR 17
Ling et al., 2015 [25] 100 CK 22 NR 64.1 33 6 12.7
Present study 33 CK 30 24 62 17 34 10.1
No. number, CK Cyberknife, LINAC linear accelerator, LF local failure, DF distant failure, MS median survival, LMC leptomeningeal carcinomatosis, mos months, NR
not reported
aMajority multi fraction SRS
bBiologically equivalent single fraction dose
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In our series, we observed an association between
male gender and overall survival which was independent
of age, RPA classification, presence of synchronous me-
tastases, and tumor histology. This association has not
been previously observed in series of SRS to resection
cavities. However, male gender has been reported as an
independent prognostic factor in analyses by Serizawa et
al. for patients treated with GK to multiple simultaneous
brain metastases [36, 37].
This study is limited by small patient numbers and its
retrospective nature. Patient selection was biased to-
wards those with higher performance status and lower
metastatic burden as compared to those who may have
been offered WBRT alone. Long-term neurocognitive
function and death due to neurologic progression were
not available for comparison to regimens using WBRT.
Doses delivered were done at the discretion of the treat-
ing physician, although the study is strengthened by in-
stitutionally based planning constraints and follow-up.
Reports of single and multi-fraction SRS using CK re-
main largely from retrospective single institution series.
Ongoing studies comparing postoperative SRS to obser-
vation (MD Anderson Cancer Center 2009–0381) and
WBRT (Intergroup N107C) will further clarify the role
of SRS after resection of a single metastasis. Neoadju-
vant SRS is an alternate treatment algorithm for local
control in large brain metastases. Phase I/II studies are
evaluating the role of neoadjuvant therapy for resectable
lesions (NCT01891318) and future studies may incorp-
orate SRS into treatments for brain metastases which
are unresectable at presentation. Findings from these
studies will continue to clarify which patients are most
suitable candidates for local therapy following resection
of a brain metastasis and to evaluate alternate treatment
paradigms in this setting.
Conclusions
Adjuvant SRS to the resection cavity for patients with
large brain metastases provides local control while spar-
ing patients potential long-term neurocognitive risk of
WBRT. Local and distant control can be achieved inde-
pendent of tumor diameter and cavity volume. Patients
with synchronous metastases may have higher rates of
distant failure when treated with local therapies alone.
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